Serum Gremlin 1 Remains Elevated Following Successful Direct-Acting Antiviral Therapy for Chronic Hepatitis C
Viruses · 14.07.2026 · 18 (7) · 773
DOI: 10.3390/v18070773 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, online erschienen am 14.07.2026. Verfasst von Kilian Weigand und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg…. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Antiviral Agents, Intercellular Signaling Peptides and Proteins. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Gremlin 1 is a fibrotic protein that increases in the liver during fibrosis. There is also evidence that gremlin 1 expression is upregulated in the livers of patients with hepatitis C virus (HCV) infection. Since gremlin 1 is a secreted protein, this study is the first to examine whether serum gremlin 1 could serve as a noninvasive marker of liver fibrosis in patients with chronic HCV infection. The study also examined whether viral clearance with direct-acting antivirals (DAAs) affects circulating gremlin 1 levels.
Methods
Serum gremlin 1 levels were measured in 30 controls and 114 patients with chronic HCV, as well as in 60 HCV patients for whom serum was available prior to therapy and at four and 12 weeks after therapy initiation and 12 weeks post-therapy.
Results
Compared with 30 healthy controls, patients with HCV exhibited significantly higher serum gremlin 1 levels. Among patients with cirrhosis, defined by noninvasive scores or ultrasound, serum gremlin 1 levels were only modestly elevated. Serum gremlin 1 levels positively correlated with markers of inflammation and aminotransferase levels in HCV patients. During antiviral therapy, serum gremlin 1 levels transiently increased four weeks after therapy initiation and returned to pretreatment levels by week 12. Even though patients were effectively cured of the virus, patients still exhibited higher serum gremlin 1 levels compared with controls at 12 weeks post-therapy.
Conclusions
Our findings indicate that chronic HCV infection is associated with elevated serum gremlin 1 levels, which do not return to normal shortly after viral cure. In contrast, serum gremlin 1 concentrations do not provide a reliable indicator of fibrosis stage in patients with chronic HCV infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany.
- Department of Gastroenterology, Gemeinschaftsklinikum Mittelrhein, 56073 Koblenz, Germany.
- Department of Internal Medicine, Klinikum Fürstenfeldbruck, 82256 Fürstenfeldbruck, Germany.
ORCID-Profile: Kilian Weigand, Christa Buechler
Zitieren
APA
Weigand, K., Peschel, G., Müller, M., & Buechler, C. (2026). Serum Gremlin 1 Remains Elevated Following Successful Direct-Acting Antiviral Therapy for Chronic Hepatitis C. Viruses, 18(7), 773. https://doi.org/10.3390/v18070773
Vancouver
Weigand K, Peschel G, Müller M, Buechler C. Serum Gremlin 1 Remains Elevated Following Successful Direct-Acting Antiviral Therapy for Chronic Hepatitis C. Viruses. 2026;18(7):773. doi:10.3390/v18070773
BibTeX
@article{Weigand2026,
author = {Weigand, Kilian and Peschel, Georg and Müller, Martina and Buechler, Christa},
title = {Serum Gremlin 1 Remains Elevated Following Successful Direct-Acting Antiviral Therapy for Chronic Hepatitis C},
journal = {Viruses},
year = {2026},
volume = {18},
number = {7},
pages = {773},
doi = {10.3390/v18070773}
}
EUVIMED